Support for Health Law Up to 48 Percent in February
Kaiser Family Foundation poll: two-thirds of Americans feel Medicaid should continue as is today
June 2017 Briefing – Allergy
Here are what the editors at HealthDay consider to be the most important developments in Allergy for June 2017. This roundup includes the latest...
Cost-Related Rx Nonadherence Highest in Young U.S. Women
One in four women report cost-related nonadherence versus one in seven men
Lanadelumab Active in Angioedema With C1 Inhibitor Deficiency
Reduced cleavage of high-molecular-weight kininogen and reduction in attacks of angioedema
C1 Inhibitor Use Reduces Attacks in Hereditary Angioedema
Subcutaneous CSL830 at doses of 40 and 60 IU reduce rate of attacks, need for rescue medication
Consensus for Early Peanut Exposure in High-Risk Infants
Interim guidance issued in response to study finding exposure lowered chances of allergy by 80 percent
Daily BCX7353 Cuts Rate of Hereditary Angioedema Attacks
Oral administration of BCX7353 at dose of ≥125 mg results in lower rate of attacks versus placebo
Recommendations Developed for Cost-Effectiveness Analyses
Concept of reference case, set of standard practices that all analyses should follow is recommended
Itepekimab Bests Placebo for Moderate-to-Severe Asthma
Incidence of events indicating loss of asthma control lower with itepekimab monotherapy in phase 2, proof-of-concept trial
CDC Director Walensky Announces Sweeping Review of Agency
Revamp would focus on improving the nation's public health workforce, data modernization, laboratory capacity, rapid response to outbreaks
